Drug Discovery: Synthesizing an End to Cancer
Creation Process
Interview with Chris Huxsoll - Mr. Huxsoll was gracious enough to allow for a very short interview covering very general topics around the world of drug development and the process of FDA approval of a drug.
Due to the fact that the process of Clinical Trials is very extensive, there are several designations given to drugs that allow for a faster process. One of these designations would be Orphan Drug. Orphan Drug is a designation given by the FDA that significantly speeds up the process as it is a highly targeted drug that is meant to be used to treat a rare disease.
During this process, new candidate medications are discovered and synthesized. The process of discovering a new drug against a chosen target for a particular disease involves high-throughput screening, which involves testing chemicals to identify their ability to modify said target. After a while, a lead compound is discovered. This lead compound, eventually, could very well become a new medicine.
There are two types of Pre-Clinical Studies: In Vitro: Research performed outside of their regular context. In Vivo: Research performed on biological entities
Studies done on large populations to compile data, and identify long-term side effects after the drug has been marketed.
During this process, new candidate medications are discovered and synthesized. The process of discovering a new drug against a chosen target for a particular disease involves high-throughput screening, which involves testing chemicals to identify their ability to modify said target. After a while, a lead compound is discovered. This lead compound, eventually, could very well become a new medicine.